Novartis announced plans to build a fourth US radioligand therapy manufacturing facility in Winter Park, Florida, as part of ...
Researchers at CSH Laboratory identified an oncogenic SRSF1–AURKA–MYC circuit driving pancreatic ductal adenocarcinoma.
Researchers at Mass General Brigham engineered a retargeted HSV-1 oncolytic virus that selectively infects glioblastoma cells, delivers five immunomodulators, and avoids healthy brain tissue. A single ...
Real-world data from nearly 400 patients with advanced, unresectable melanoma show that a flipped, lower-dose ipilimumab regimen increased objective response rates from 37% to 49%, tripled median ...
The Phase 3 EV-304 KEYNOTE-B15 trial showed that perioperative enfortumab vedotin (PADCEV) plus pembrolizumab (Keytruda) significantly improved event-free survival and overall survival versus ...
The FDA has approved RYBREVANT FASPRO, the first subcutaneous amivantamab, for EGFR-mutated NSCLC, enabling five-minute administration with fewer infusion reactions. In Phase III PALOMA-3, ...
Researchers at the Johns Hopkins KCC have developed a TRBC2-targeted antibody-drug conjugate for T-cell lymphomas and leukemias, addressing half of patients previously lacking precision options. The ...
The FDA has approved T-DXd (Enhertu) plus pertuzumab as first-line therapy for unresectable or metastatic HER2-positive breast cancer, the first new option in over a decade. In the Phase III ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback